Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

78.15USD
22 Apr 2019
Change (% chg)

$0.58 (+0.75%)
Prev Close
$77.57
Open
$77.59
Day's High
$79.09
Day's Low
$77.50
Volume
1,145,039
Avg. Vol
1,738,665
52-wk High
$107.24
52-wk Low
$75.77

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $115,518.60
Shares Outstanding(Mil.): 1,478.17
Dividend: 1.07
Yield (%): 5.48

Financials

  ABBV.N Industry Sector
P/E (TTM): 21.56 62.06 62.40
EPS (TTM): 3.62 -- --
ROI: 11.99 12.17 11.78
ROE: -- 13.11 12.61

FDA puts partial hold on clinical trials of AbbVie's cancer drug

AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.

19 Mar 2019

UPDATE 1-FDA puts partial hold on clinical trials of AbbVie's cancer drug

March 19 AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.

19 Mar 2019

FDA puts partial hold on clinical trials of AbbVie's cancer drug

March 19 AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer treatment Venclexta for multiple myeloma.

19 Mar 2019

BRIEF-AbbVie Says FDA Placed A Partial Clinical Hold On All Clinical Trials Evaluating Venetoclax For Investigational Treatment Of Multiple Myeloma

* ABBVIE PROVIDES UPDATE ON VENCLEXTA®/VENCLYXTO® (VENETOCLAX) MULTIPLE MYELOMA PROGRAM

19 Mar 2019

Factbox: Pharma company executives to testify at U.S. Senate drug price hearing

Executives from seven of the world's largest pharmaceutical companies are set to testify about high U.S. prescription drug prices at a U.S. Senate hearing on Tuesday, amid an intensifying focus on the industry's practices by both political parties.

25 Feb 2019

AbbVie expects steeper decline in Humira's overseas sales; shares fall

AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

25 Jan 2019

UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall

Jan 25 AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

25 Jan 2019

AbbVie not contemplating big deals - CEO

Jan 25 AbbVie Inc is not considering a big merger or an acquisition, Chief Executive Officer Richard Gonzalez said on Friday, allaying speculations of the company launching a bid for Bristol-Myers Squibb.

25 Jan 2019

AbbVie profit misses as Humira faces biosimilar challenge in Europe

AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.

25 Jan 2019

AbbVie profit misses as Humira faces biosimilar challenge in Europe

Jan 25 AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.

25 Jan 2019

Earnings vs. Estimates